GlassScriptPhysician profile
James S Swindle
NPI 1225006737
$1,258.69
in general payments reported to CMS, 2019-2025
14 companies · $319 in 2025
The $319 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $58.74 · 2021: $65.39 · 2022: $148 · 2023: $298 · 2024: $210 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $417.41 | 2022-2025 | Azstarys |
| Pfizer INC. | $246.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $168.49 | 2019-2025 | Bexsero, Rotarix, Arexvy |
| Ironshore Pharmaceuticals INC. | $113.88 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $83.55 | 2023-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $76.95 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $33.74 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $33.59 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.23 | 2019 | |
| Novo Nordisk INC | $15.36 | 2024 | |
| Sobi, INC | $15.11 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.39 | 2021 | |
| Genentech USA, INC. | $12.03 | 2019 | |
| Shire North American Group INC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Swindle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.